+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Bladder Cancer Market 2020-2026

  • ID: 5148066
  • Report
  • August 2020
  • Region: United States
  • Orion Market Research Private Limited

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
US Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

The US bladder cancer market is estimated to grow modestly at a CAGR of around 9.7% during the forecast period. The US contributes significantly to the growth of the bladder cancer treatment market in North America. The increasing aging population across the country is augmenting the growth of the market. According to the American Cancer Society, bladder cancer occurs mainly in older people, with an average age at the time of diagnosis being 73 years. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060.

Bladder cancer is the fourth most common cancer in men; however, it is less common in women. American Cancer Society has provided bladder cancer statistics for 2019 in the US. The society estimates that around 80,470 new cases of bladder cancer will be diagnosed in the country, of which 61,700 will be in men and 18,770 will be in women. This prevalence of bladder cancer will lead to mortalities across the country. The US consists of some of the key players of the bladder cancer market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.

US bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.

The companies which are contributing to the growth of the US bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Johnson & Johnson Services, Inc., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in April 2019, Johnson & Johnson Services, Inc.’s drug Balversa became the first targeted therapy for bladder cancer after an FDA approval for patients with mutations in the FGFR gene. Balversa (erdafitinib) is the first drug in the class to reach the US market. The FDA granted accelerated approval for the drug in patients with FGFR-mutated locally advanced or metastatic urothelial carcinoma (mUC) who have previously been treated with platinum-based chemotherapy and seen their disease progress.

Research Methodology:

The market study of the US bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • White papers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. US Bladder Cancer Market Research and Analysis by Cancer Type
2. US Bladder Cancer Market Research and Analysis by Diagnosis
3. US Bladder Cancer Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the US bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the US bladder cancer market.
  • Insights about market determinants which are stimulating the US bladder cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. US Bladder Cancer Market by Cancer Type
5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
5.1.2. Squamous Cell Bladder Cancer
5.1.3. Adenocarcinoma
5.1.4. Others (Sarcomas, Carcinoma in Situ)
5.2. US Bladder Cancer Market by Diagnosis
5.2.1. Cystoscopy
5.2.2. Biopsy
5.2.3. Urinalysis
5.2.4. Urine Cytology
5.2.5. Intravenous Pyelogram (IVP)
5.2.6. Others (Biomarkers)
5.3. US Bladder Cancer Market by Treatment
5.3.1. Surgery
5.3.2. Chemotherapy
5.3.3. Immunotherapy
5.3.4. Radiation Therapy
5.3.5. Others (Targeted Therapy)

6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. EMD Serono, Inc.
6.7. F. Hoffmann-La Roche Ltd.
6.8. Genentech Inc.
6.9. GlaxoSmithKline Plc
6.10. Johnson & Johnson Services, Inc.
6.11. Merck & Co., Inc.
6.12. Pfizer Inc.
6.13. Spectrum Pharmaceuticals, Inc.
6.14. Taris Biomedical LLC
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
Note: Product cover images may vary from those shown
Adroll
adroll